Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
myFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • Americas
    • Middle East and North Africa
    Most Read
    • France to offer mRNA jabs as second dose after AstraZeneca 
    • Prince Philip dies aged 99
    • AstraZeneca cuts this week’s vaccine deliveries to EU by half
    • Ministers announce Covid testing plan to reopen travel from England
    • Experts back UK age limit for rollout of AstraZeneca vaccine
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • ‘The next wave has started.’ Covid surge in Michigan raises alarm
    • London Whale lessons for Credit Suisse and Nomura
    • A grand bargain: how the radical US corporate tax plan would work
    • US offers new plan in global corporate tax talks
    • BlackRock secures largest-ever ETF launch as green investing wave builds
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Carney’s stumble at Brookfield intensifies focus on ‘net zero’ claims
    • Spac boom under threat as deal funding dries up
    • Lex Greensill cited David Cameron in bungled Australian lobbying
    • Suspect Sanjeev Gupta invoices used in Greensill loans raise fraud concerns
    • London Whale lessons for Credit Suisse and Nomura
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    Most Read
    • Inflation might be the way out of the debt crisis
    • Why Coinbase’s stellar earnings are not what they seem
    • Exit of Cuba’s last Castro brings curtain down on revolutionary era
    • US government debt hit as analysts braced for $370bn in Treasury sales
    • Global stocks rise after Fed vows continued support for recovery
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • It’s mostly sociopaths who want to go back to the office
    • London Whale lessons for Credit Suisse and Nomura
    • Blockchain may change equities trading for good
    • Shoppers are paying high prices for closing borders
    • Inflation might be the way out of the debt crisis
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • FT business books: April edition
    • Lights, camera, childcare: on-set nurseries aim to transform film industry
    • Burnout: the next health crisis?
    • Covid has upended the out-of-office email. Hooray!
    • The way to avoid turning staff into lab rats in a hybrid work experiment
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Minouche Shafik: ‘I don’t have to be the smartest person in the room’
    • Book the cut, hold the blow dry: the new approach to salon visits
    • Terraced tearaways: how period homes became modern
    • Socialising is back — and I’m already eyeing the couch
    • Your pension, your risk, your choice
  • How to Spend It
  • Sign In
  • Subscribe
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • How to Spend It
Financial Times
  • Sign In
  • Subscribe

GlaxoSmithKline PLC

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Monday, 29 March, 2021
    Covid-19 vaccines
    GSK to help manufacture 60m doses of Novavax Covid vaccine in UK

    Drugmaker will ‘fill and finish’ as-yet-unapproved jabs as talks continue over EU export controls

  • Wednesday, 24 March, 2021
    GSK says Trump vaccine tsar accused of sexual harassment

    Moncef Slaoui forced out as chair of the board of drugmaker’s subsidiary Galvani Bioelectronics

  • Thursday, 11 March, 2021
    LexPharmaceuticals sector
    GSK/Vir: antibody booster can work wonders Premium

    Faith in monoclonal antibodies pays off with promising results

  • Thursday, 11 March, 2021
    Coronavirus treatment
    GSK Covid treatment shows ‘profound efficacy’ in initial trial

    Data from 583 patients shows 85% reduction in hospitalisation or death

  • Wednesday, 10 March, 2021
    News in-depthPharmaceuticals sector24 min
    Covid-19 and the business of vaccines

    New vaccine producers and mRNA technology are shaking up the market

  • Tuesday, 16 February, 2021
    News in-depthCovid-19 vaccines
    Why the three biggest vaccine makers failed on Covid-19

    GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology

  • Wednesday, 3 February, 2021
    City Bulletin
    GlaxoSmithKline agrees tie-up with Nasdaq-listed CureVac to develop Covid-19 vaccines Premium

    Cynthia Carroll joins Glencore board, Bezos to step aside

  • Wednesday, 3 February, 2021
    Covid-19 vaccines
    GSK and CureVac to develop vaccines to tackle Covid variants

    €150m deal aims to have a vaccine ready for use in 2022

  • Friday, 18 December, 2020
    Biotech
    GSK invests in new field of genetic rebalancing

    Pharma giant to co-lead funding round for Cambridge biotech start-up Adrestia

  • Promoted Content
  • Friday, 11 December, 2020
    Coronavirus treatment
    Sanofi/GSK delay vaccine rollout and Australia ditches trial

    European partnership hit by dosage issues while Canberra project is derailed by false positive HIV tests

  • Tuesday, 3 November, 2020
    LexESG investing
    GSK/ESG funds: flower power Premium

    Pharma group’s new buzz phrase is ‘net positive impact on nature’

  • Wednesday, 28 October, 2020
    GSK reassures on profits as standard vaccination levels recover

    UK group says treatments for diseases other than Covid-19 have picked up after lockdown disruption

  • Sunday, 2 August, 2020
    The FT ViewThe editorial board
    Pandemic puts countries’ resilience to the test

    Governments must resist the urge towards protectionism

  • Friday, 31 July, 2020
    Coronavirus treatment
    US agrees to buy Sanofi-GSK Covid-19 vaccine

    Washington will pay up to $2.1bn to speed up development and secure an initial 100m doses

  • Wednesday, 29 July, 2020
    GlaxoSmithKline warns of hit to vaccines business

    UK drugmaker says earnings forecast will be under threat unless immunisation rates pick up

  • Wednesday, 29 July, 2020
    LexCoronavirus pandemic
    Sanofi/GSK: boosterism Premium

    Both companies stand to benefit from the spotlight on immunisation

  • Wednesday, 29 July, 2020
    Coronavirus treatment
    UK strikes deal for 60m Covid-19 vaccine doses with Sanofi and GSK

    Advance purchase agreement depends on clinical trials starting in September

  • Monday, 20 July, 2020
    LombardCat Rutter Pooley
    GSK shown up by AstraZeneca yet again

    Waiting on turnround at GSK; waiting on court decision over business interruption insurance

  • Monday, 20 July, 2020
    GSK scoops up close to 10% of German vaccine producer CureVac

    Deal increases UK drugmaker’s exposure to potential coronavirus vaccines

  • Monday, 13 July, 2020
    Emma Walmsley
    Antimicrobial resistance is the next battle

    Covid-19 is a warning that we must develop drugs to treat future threats

  • Tuesday, 7 July, 2020
    Pharmaceuticals sector
    GSK’s anti-HIV drug better at preventing infection, trial finds

    Study with 4,566 people found cabotegravir is more effective than current care standard

  • Thursday, 28 May, 2020
    Coronavirus pandemic
    GSK targets production of 1bn doses of coronavirus vaccine booster

    Drugmaker says adjuvant would allow for more doses and offer longer-lasting immunity

  • Wednesday, 27 May, 2020
    News in-depthThe Big Read
    Drug wars: how AstraZeneca overtook GSK in UK pharma

    With new cancer drugs and a vaccines partnership with Oxford university, AZ’s turnround has boosted the industry in Britain

  • Friday, 24 April, 2020
    Coronavirus pandemic
    Drugmakers urged to collaborate on coronavirus vaccine 

    Investors say competition needs to be put aside for the greater good

  • Tuesday, 14 April, 2020
    Coronavirus pandemic
    GSK and Sanofi team up on Covid-19 vaccine

    Rival drugmakers both hold ‘piece of the puzzle’, says David Loew

Previous You are on page 1 Next

Topics related to Health & pharmaceuticals

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

FT LiveShare News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingContracts & Tenders
Executive Job SearchAdvertise with the FTFollow the FT on TwitterFT TransactSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School Rankings
Enterprise ToolsNews feedNewslettersCurrency Converter
More from the FT Group
Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2021. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • Americas
    • Middle East and North Africa
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • How to Spend It
  • Special Reports
  • FT recommends
  • Graphics
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In